Literature DB >> 33867038

An all-in-one telomerase assay based on CRISPR-Cas12a trans-cleavage while telomere synthesis.

Peihang Yu1, Tiantian Yang1, Decai Zhang1, Lulu Xu2, Xiaoxue Cheng1, Shijia Ding2, Wei Cheng3.   

Abstract

As one of the crucial factors associated with human life span and cancer progression, telomerase is regarded as an emerging biomarker for cancer diagnosis. Therefore, a facile, rapid and sensitive approach for telomerase activity detection with point-of-care (POC) diagnosis potential is in great demands. Herein, an all-in-one telomerase activity detection assay was established based on the telomere synthesis activated CRISPR-Cas12a system. A telomerase extension reaction generated telomere repeats sequences (TTAGGG)n, which was recognized by a customized CRISPR-guided RNA (crRNA) simultaneously, and finally activated a typical trans-cleavage based CRISPR-Cas12a detection assay. With the inherent sensitivity of CRISPR-Cas12a, this approach achieved a great linear regression ranging from 100 to 2000 HeLa cells and a limitation of detection down to 26 HeLa cells. Moreover, by using the proposed method, telomerase can be detected in one pot under isothermal condition (37 °C) by a simple and fast workflow (one step within 1 h). Due to its excellent performance, this all-in-one method shows great potential in POC detection of the telomerase activity.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  All-in-one; CRISPR-Cas12a; Point-of-care diagnosis; Telomerase activity; Trans-cleavage

Mesh:

Substances:

Year:  2021        PMID: 33867038     DOI: 10.1016/j.aca.2021.338404

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  1 in total

Review 1.  CRISPR/Cas: A New Tool in the Research of Telomeres and Telomerase as Well as a Novel Form of Cancer Therapy.

Authors:  Mahendar Porika; Radhika Tippani; Gabriele Christine Saretzki
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.